Skip to Content
Søg Menu

EHA 2025 I The European Hematology Association

EHA 2025

EHA 2025: Improved Outcomes in High-Risk MCL with Acalabrutinib Combination Therapy 

  • / Jan Andreasen

Malin Rasmussen

EHA 2025: Radiotherapy in FL Linked to Low Relapse Rates

/ Malin Rasmussen
EHA25Lymfom Play the Video
Frida Bugge Askeland

EHA 2025: Impact of Treating MRD Relapse Post 1L in Multiple Myeloma

/ Frida Bugge Askeland
EHA25Myelomatose Play the Video

EHA 2025: Novel Immune Escape Pathway in AML Identified and Successfully Blocked

/ Hæmatologi / Carl Sandén

EHA 2025: Tripled Cardiac Morbidity Risk After Hodgkin Lymphoma Therapy

/ Hæmatologi / Sara Rossetti

EHA 2025: Overcoming Venetoclax Resistance

/ Hæmatologi / Justinas Daraskevicius

EHA 2025: First-in-Class BTK Degrader Drives Strong Responses in R/R CLL/SLL

/ Hæmatologi / Lydia Scarfò
Henrik Frederiksen

EHA 2025: ADHD Treatment medication alleviate Fatigue in Patients with Malignant Diseases show Danish Study

/ Henrik Frederiksen
EHA25 Play the Video
Mats Jerkeman

Several Options for Frontline Treatment of MCL

/ Mats Jerkeman
EHA25Lymfom Play the Video
Paolo Ghia

EHA 2025: Durable Undetectable MRD Responses with Acalabrutinib in CLL

/ Paolo Ghia
EHA25CLL Play the Video
Mats Jerkeman

EHA 2025: Signs of Functional Cure for MCL in 25 Years Nordic Follow-Up Study

/ Mats Jerkeman
EHA25Lymfom Play the Video
Chan Cheah

EHA 2025: Sonrotoclax + Zanubrutinib Show Durable Responses in R/R CLL/SLL

/ Chan Cheah
EHA25CLL Play the Video
Paolo Ghia

EHA 2025: Zanubrutinib Effective as First-Line CLL/SLL Therapy Regardless of del(17p)

/ Paolo Ghia
EHA25CLL Play the Video
Hent flere

Mest sete

MEDtalks

EHA 2025: Nordic AML Group Explores Optimized Regimen for AML Patients

/ Hæmatologi / Anne Louise Tølbøll Sørensen

EHA 2025: TG01 Shows Promise in KRAS-Mutated Myeloma

/ Hæmatologi / Hanne Norseth

The 2025 EHA Award Recipients

/ Hæmatologi / Amanda Feldballe Bernholm

EHA 2023

Carsten Niemann

Overlevelsesgevinst for skrøbelige CLL-patienter i behandling med Imbruvica og Venclyxto

/ Carsten Utoft Niemann
EHA23CLL Play the Video

Ibrutinib keeps on delivering now as first-line treatment for older patients with mantle cell lymphoma

/ BestPractice Nordic
EHA22Lymfom

Superior safety profile for decitabine vs chemotherapy for older patient with AML

/ BestPractice Nordic
EHA22AML
Anna Sureda Balari

Epcoritamab with Rituximab and Lenalidomide (R2) for Patients with High-Risk Follicular Lymphoma

/ Anna Sureda Balari
EHA23Lymfom Play the Video
Mark Levis

Gilteritinib for Patients with Newly Diagnosed AML

/ Mark Levis
EHA23Ernæring Play the Video
Arnon Kater

MURANO Study Supports the Use of Fixed-Duration VenR in R/R CLL

/ Arnon Kater
EHA23CLL Play the Video
Evangelos Terpos

Daratumumab Combination Shows Positive Responses in Pretreated R/R Multiple Myeloma

/ Evangelos Terpos
EHA23Myelomatose Play the Video
Ryan Jacobs

News from EHA23 – A Promising Treatment Option for Follicular Lymphoma

/ Ryan Jacobs
EHA23Lymfom Play the Video
Barbara Eichhorst

What is New from EHA23 Regarding Treatment Strategies in First-Line CLL?

/ Barbara Eichhorst
EHA23CLL Play the Video
Eva Futtrup Maksten

Risk of Dementia in Older Patients Treated with Chemotherapy for Lymphoma

/ Eva Futtrup Maksten
EHA23LymfomDemens Play the Video

Belamaf and Dexamethasone – Safe, Effective Multiple Myeloma Treatment

/ Evangelos Terpos / Jan Andreasen
EHA23Myelomatose
Alan Z. Skarbnik

New Research from EHA23 Points to Similar Effectiveness of Acalabrutinib and Zanubrutinib in R/R CLL Treatment

/ Alan Z. Skarbnik
EHA23CLL Play the Video
Hent flere

Højdepunkter fra EHA webinar 2022

Martin Hutchings

Hidtil højeste overall survival udfordrer 1.-linjebehandling ved Hodgkin lymfom

/ Martin Hutchings
Lymfom Play the Video
Martin Hutchings

To bispecifikke antistoffer er på vej mod godkendelse mod diffust storcellet B-celle lymfom

/ Martin Hutchings
B-celle lymfomLymfom Play the Video
Carsten Utoft Niemann

Tidsbegrænset venetoclax-baseret kombinationsbehandling opnår bedre PFS og MRD-negativitet ved behandling af CLL

/ Carsten Utoft Niemann
CLL Play the Video
Carsten Utoft Niemann

Sekventering og vurdering af behandlingsforløb ved CLL

/ Carsten Utoft Niemann
EHA22CLL Play the Video

MEDtalks fra EHA 2022

AML

ASH 2024: Nyt om AML i dansk perspektiv

/ Hæmatologi / Hans Beier Ommen

ASH 2024: AML-forskning tar nye steg med CPX-behandling og meninhemmere

/ Hæmatologi / Bjørn Tore Gjertsen

Swedish Result for Cytarabine Treatment of Secondary AML is Better than the Register Studies

/ Hæmatologi / Gunnar Juliusson

Genomic Subtypes of AML Determines Sensitivity to NK Cell Cytotoxicity

/ Hæmatologi / Hanna Duàn

Cytarabine Dose Intensification Improves Survival in Older Patients with AML

/ Hæmatologi / Gunnar Juliusson
Se oversigt

CLL

Dansk Aften ASH 2024: Nye fremskridt i behandling af CLL

/ Hæmatologi / Emelie Hamotal Curovic Rotbain

High Infection Burden and Mortality in CLL Patients: A Call for Action

/ Hæmatologi / Ingrid Glimelius

Pirtobrutinib Outperforms Investigators’ Choice in Relapsed/Refractory CLL After BTK Inhibitor Therapy

/ Hæmatologi / Paolo Ghia

Deep and Durable Response of Fixed-Duration Acalabrutinib in Combination with Venetoclax, +/- Obinutuzumab in Previously Untreated Adults with CLL

/ Hæmatologi / Jennifer R. Brown

Acalabrutinib Shows Promise for Elderly CLL Patients

/ Hæmatologi / Florian Simon
Se oversigt

Lymfom

Ingen ændringer i behandlingen inden for lymfom efter ASH 2024, men mange vigtige updates

/ Hæmatologi / Tarec Christoffer El-Galaly

Machine learning kan reducere unødvendige indlæggelser af kræftpatienter

/ Hæmatologi / Alexander Fuglkjær

Zilovertamab Vedotin in Mantle Cell Lymphoma: Promising Results from ASH 2024

/ Hæmatologi / Ingrid Glimelius

High Mortality Rate for Patients with Mantle Cell Lymphoma with a Second Primary Malignancy

/ Hæmatologi / Ingrid Glimelius

The Majority of Patients with Mantle Cell Lymphoma Probably Don’t Need Auto-Transplant in the Current Treatment Era

/ Hæmatologi / Timothy S. Fenske
Se oversigt

Myelomatose

EHA 2025: Impact of Treating MRD Relapse Post 1L in Multiple Myeloma

/ Hæmatologi / Frida Bugge Askeland

ASH 2024: Viktige funn som kan endre behandlingen av myelomatose

/ Hæmatologi / Fredrik Schjesvold

Novel Risk Stratification Method for Bone Disease in Multiple Myeloma Patients Minimizes Radiation Exposure and Lowers Economic Burden

/ Hæmatologi / Muhammad Kashif

Daratumumab Monotherapy Shows Clinical Benefit for Early Intervention for Patients with High-Risk Smoldering Multiple Myeloma

/ Hæmatologi / Meletios A. Dimopoulos

Positive Outcome of Steroid Replacement in Transplant-Ineligible Myeloma

/ Hæmatologi / Frida Bugge Askeland
Se oversigt

Abstracts fra EHA 2022

A novel CAR-T cell therapy thas proven highly effective for patients with RRMM

/ Hæmatologi / BestPractice Nordic

A new phase 3 trial shows significantly prolonged overall survival for patients with AML

/ Hæmatologi / BestPractice Nordic

Improved PFS is achievable using targeted therapy combinations with venetoclax in fit patients with treatment naïve CLL 

/ Hæmatologi / BestPractice Nordic

Treatment of Burkitt lymphoma with DA-EPOCH-R is associated with significant less infectious complications, transfusions, and hospitalization days 

/ Hæmatologi / BestPractice Nordic

Phase 2 study update: Epcoritamab demonstrates clinically meaningful and compelling efficacy in the treatment of R/R large B-cell lymphoma 

/ Hæmatologi / BestPractice Nordic

Phase 2 study update: Epcoritamab demonstrates clinically meaningful and compelling efficacy in the treatment of R/R large B-cell lymphoma 

  • / BestPractice Nordic

Se highlights EHA webinar 2022

Carsten Utoft Niemann

Sekventering og vurdering af behandlingsforløb ved CLL

/ Carsten Utoft Niemann
EHA22CLL Play the Video
Martin Hutchings

To bispecifikke antistoffer er på vej mod godkendelse mod diffust storcellet B-celle lymfom

/ Martin Hutchings
B-celle lymfomLymfom Play the Video
Carsten Utoft Niemann

Tidsbegrænset venetoclax-baseret kombinationsbehandling opnår bedre PFS og MRD-negativitet ved behandling af CLL

/ Carsten Utoft Niemann
CLL Play the Video
Martin Hutchings

Hidtil højeste overall survival udfordrer 1.-linjebehandling ved Hodgkin lymfom

/ Martin Hutchings
Lymfom Play the Video

Gå ikke glip af det nyeste fra Hæmatologi

Skriv dig på og få nye artikler, MEDtalks og magasiner i din indbakke

Send mig seneste nyt fra hæmatologi

Mere fra EHA 2022

Daniel Kristensen

Tillæg af andengenerations-FLT3-inhibitor til intensiv kemoterapi og konsolidering hos voksne med AML

/ Daniel Kristensen
EHA22AML Play the Video
Agoston Gyula Szabo

Værdien af højdosisbehandling som tillæg til Rvd induktion og konsolidering ved myelomatose

/ Agoston Gyula Szabo
EHA22Myelomatose Play the Video
Carsten Utoft Niemann

Sekventering og vurdering af behandlingsforløb ved CLL

/ Carsten Utoft Niemann
EHA22CLL Play the Video

Mere fra EHA 2021

Paolo Strati

Phase 1 Results in SIRPα Antibody CC-95251 in Combination with Rituximab in Patients with R/R NHL

/ Paolo Strati
EHA22Lymfom Play the Video
Kirsten Grønbæk

Hvad har GDPR betydet for den nordiske forskningsscene? Vigtigste take-aways fra EHA med Kirsten Grønbæk

/ clara
EHA22 Play the Video
Othman Al-sawaf

CLL14 study five-year results: Significantly superior efficacy for Ven-Obi

/ Othman Al-Sawaf
EHA22CLL Play the Video
Daniel Kristensen

Nyt landsdækkende studie stiller spørgsmålstegn ved betydningen af dosisreduktion hos overvægtige AML-patienter

/ Daniel Kristensen
EHA22AML Play the Video
Jean-Marie Michot

Novel oral agent with promising result as second-line treatment option for patients with T-Cell Lymphoma

/ Jean-Marie Michot
EHA22Lymfom Play the Video
Paul Richardson

A new randomized study suggests an improved depth of response and PFS for patients relapsing on Lenalidomide

/ Paul G. Richardson
EHA22Myelomatose Play the Video
Læs mere
Arnon Kater

The main clinical message from the Five-Year Analysis of Murano Study

/ Arnon P. Kater
EHA22CLL Play the Video
Paul Richardson

Longer PFS and higher ORR for frailty patients with R/R Multiple Myeloma treated with PVd than Vd

/ Paul G. Richardson
EHA22Myelomatose Play the Video
Jakob Nordberg Nørgaard

A new study shows that PTCD and MRD are complementary and necessary for doing a whole assessment on patient-response for myeloma patients

/ Jakob Nordberg Nørgaard
EHA22Myelomatose Play the Video
Back to top